298 related articles for article (PubMed ID: 26351383)
21. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.
Takashima S; Kato J; Hiraoka S; Nakarai A; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H; Tanaka T; Yamamoto K
Am J Gastroenterol; 2015 Jun; 110(6):873-80. PubMed ID: 25823769
[TBL] [Abstract][Full Text] [Related]
23. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
[TBL] [Abstract][Full Text] [Related]
24. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
25. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
[TBL] [Abstract][Full Text] [Related]
26. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
[TBL] [Abstract][Full Text] [Related]
27. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
[TBL] [Abstract][Full Text] [Related]
28. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
[TBL] [Abstract][Full Text] [Related]
29. Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease.
Verdejo C; Hervías D; Roncero Ó; Arias Á; Bouhmidi A; Lorente R; Salueña I; Lucendo AJ
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1521-1527. PubMed ID: 30303822
[TBL] [Abstract][Full Text] [Related]
30. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.
Faubion WA; Fletcher JG; O'Byrne S; Feagan BG; de Villiers WJ; Salzberg B; Plevy S; Proctor DD; Valentine JF; Higgins PD; Harris JM; Diehl L; Wright L; Tew GW; Luca D; Basu K; Keir ME
Am J Gastroenterol; 2013 Dec; 108(12):1891-900. PubMed ID: 24126633
[TBL] [Abstract][Full Text] [Related]
31. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
Zollner A; Schmiderer A; Reider SJ; Oberhuber G; Pfister A; Texler B; Watschinger C; Koch R; Effenberger M; Raine T; Tilg H; Moschen AR
J Crohns Colitis; 2021 Jan; 15(1):43-54. PubMed ID: 32556317
[TBL] [Abstract][Full Text] [Related]
32. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis.
Walsh A; Kormilitzin A; Hinds C; Sexton V; Brain O; Keshav S; Uhlig H; Geddes J; Goodwin G; Peters M; Collins G; Travis S
J Crohns Colitis; 2019 Mar; 13(4):424-430. PubMed ID: 30445625
[TBL] [Abstract][Full Text] [Related]
33. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
34. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy.
Kawashima K; Ishihara S; Yuki T; Fukuba N; Sonoyama H; Kazumori H; Yamashita N; Tada Y; Kusunoki R; Oka A; Oshima N; Mishima Y; Moriyama I; Kinoshita Y
Inflamm Bowel Dis; 2017 Nov; 23(11):2027-2034. PubMed ID: 28817462
[TBL] [Abstract][Full Text] [Related]
35. Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease.
Sollelis E; Quinard RM; Bouguen G; Goutte M; Goutorbe F; Bouvier D; Pereira B; Bommelaer G; Buisson A
World J Gastroenterol; 2019 May; 25(19):2354-2364. PubMed ID: 31148906
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Fecal Inflammatory Markers in Crohn's Disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Keenan JI; Leach S; Burgess L; Aitchison A; Gorelik A; Liew D; Day AS; Gearry RB
Inflamm Bowel Dis; 2016 May; 22(5):1086-94. PubMed ID: 26818420
[TBL] [Abstract][Full Text] [Related]
37. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
38. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
[TBL] [Abstract][Full Text] [Related]
39. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease.
Pavlidis P; Gulati S; Dubois P; Chung-Faye G; Sherwood R; Bjarnason I; Hayee B
Scand J Gastroenterol; 2016 Dec; 51(12):1447-1452. PubMed ID: 27400728
[TBL] [Abstract][Full Text] [Related]
40. Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.
Baillet P; Cadiot G; Goutte M; Goutorbe F; Brixi H; Hoeffel C; Allimant C; Reymond M; Obritin-Guilhen H; Magnin B; Bommelaer G; Pereira B; Hordonneau C; Buisson A
World J Gastroenterol; 2018 Feb; 24(5):641-650. PubMed ID: 29434453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
